About Nimble Therapeutics
Nimble Therapeutics is a Healthcare company based in Madison (United States) founded in 2019, and was acquired by AbbVie in December 2024. Combinatorial chemistry services for peptide-based drug discovery are provided. Nimble Therapeutics has raised $10 million across 1 funding round from investors including AbbVie and Telegraph Hill Partners. The company has 24 employees. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is Nimble Therapeutics, Inc. Its competitors include NTxBio, Applied BioMath and Enveda; 3 of its 3 listed competitors have raised funding.
Company details
Nimble Therapeutics was founded in 2019 in Madison, United States, within the biotechnology sector. Drug discovery services centered on combinatorial chemistry are offered, with a focus on peptide technologies. A chemical synthesis platform has been developed to facilitate the creation and evaluation of various peptides, including scaffolded natural and modified macrocyclic peptidomimetics. Operations emphasize efficient screening processes for potential therapeutic compounds in the pharmaceutical industry.
- Headquarters Madison, United States
- Employees 24
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website nimbletherapeutics.com
- Social LinkedIn
- Acquired by AbbVie (Dec 2024)
- Legal Name Nimble Therapeutics, Inc
Funding Insights of Nimble Therapeutics
Nimble Therapeutics has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series A round of $10 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Series A — $10M
- First Round $10M
(Apr 2019)
- Investors Count 1
All 1 funding rounds of Nimble Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $10M | Series A | – | Telegraph Hill Partners | – |
2 investors in total: 2 institutional.
Investors in Nimble Therapeutics
Nimble Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie and Telegraph Hill Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science, medical device and healthcare companies | thpartners.net | San Francisco, United States | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States |
Investor details for Nimble Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nimble Therapeutics
15 people are tracked at Nimble Therapeutics (3 in leadership, 3 in board & advisors, 9 in team); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Jigar Patel | Founder & CEO | Leadership |
Andrew Wagner | Director, Software & Engineering | Leadership |
Brad Garcia | VP, Corporate Development | Leadership |
Dan Zabrowski | Chairman | Board & advisors |
Paul D. Grossman | Director | Board & advisors |
Deval A. Lashkari | Director | Board & advisors |
Eric Dauenhauer | Principal Engineer | Team |
Paulina Aguilar Robles | Scientist I | Team |
Brett Roberts | Senior Scientist II | Team |
Adam Cartwright | Scientist | Team |
Ryan Bannen | Principal Research Scientist I, Informatics | Team |
Madison Gryttr | Scientist | Team |
Kathleen Steigerwald, M.S. | Scientist II | Team |
Alex Buchberger | Scientist 2 | Team |
Sravanthi Devi Guggilapu, Ph.D. | Sr Scientist Ll | Team |
Complete people profiles for Nimble Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Nimble Therapeutics
3 dated milestones of Nimble Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Nimble Therapeutics is founded.
- Funding First funding round of $10.0M.
- Exit Acquired by AbbVie.
Competitors of Nimble Therapeutics
Nimble Therapeutics has 3 listed competitors in our database, 3 of them funded. They include NTxBio, Applied BioMath and Enveda.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ntxbio.com | 2016 | Santa Fe, United States | $74.76M | Provider of bio informatics platform to develops biologics and therapeutics | ||
| appliedbiomath.com | 2013 | Cambridge, United States | $2.32M | 61 | Systems biology and pharmacology modeling services to aid drug discovery and development | |
| enveda.com | 2019 | Boulder, United States | $845M | Provider of AI-based platform to decipher the chemistry of nature and develop new medicines |
Detailed competitors of Nimble Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Nimble Therapeutics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nimble Therapeutics
Complete news archive for Nimble Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nimble Therapeutics
Nimble Therapeutics was founded in 2019.
Nimble Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Nimble Therapeutics is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series A of $10M, raised on Apr 2019.
Nimble Therapeutics has 24 employees.
Nimble Therapeutics was founded in 2019 in Madison, United States, within the biotechnology sector. Drug discovery services centered on combinatorial chemistry are offered, with a focus on peptide technologies. A chemical synthesis platform has been developed to facilitate the creation and evaluation of various peptides, including scaffolded natural and modified macrocyclic peptidomimetics. Operations emphasize efficient screening processes for potential therapeutic compounds in the pharmaceutical industry.
Nimble Therapeutics's top competitors include NTxBio, Enveda and Applied BioMath.
Nimble Therapeutics has 2 investors. Key investors include AbbVie, and Telegraph Hill Partners.
Nimble Therapeutics operates through Nimble Therapeutics, Inc.
Yes. Nimble Therapeutics was acquired by AbbVie in December 2024.